active
ACTIVE SINCE: 2022-2024

Hit-to-Lead development of novel Astellas compounds with antimalarial activity

The Global Health Innovative Technology (GHIT) Fund announced a total of approximately 740 million yen (US$6.4 million*) to invest in three partnerships to develop new lifesaving tools for malaria.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Astellas will contribute to the design of new analogues and interpretation of the data using state of the art computer-aided drug design techniques.
Product Development Partnerships 1
Intergovernmental Organizations and Multilaterals 1
Objectives

The objective of the project is to identify at least 1 novel compound series meeting MMV Early Lead Criteria (1) that has clear potential for further development and progression to Lead Optimization.

GHIT will invest 131 million yen (US$1.1 million) in identification of lead compound series with antimalarial activity that has clear potential for further development and progression to lead optimization. Previous project supported by GHIT, four novel hit compounds with antimalarial activity were identified from screening of Astellas’s 20,000 compounds. The compounds will be designed to explore both structure activity relationships and scope for structural modification to improve the compound profile such as potency, DMPK, and safety.

The project will consist of two phases. The first 6-month phase will involve the synthesis and profiling of small set of compounds designed around each of the four hit compounds identified in the previous project. The compounds will be designed to explore both structure activity relationships (SAR) and scope for structural modification to improve the compound profile (potency, DMPK, safety, etc.). Two series will be selected for Hit-to-Lead studies. The second 18-month phase of the project will involve the optimization of the series (prioritizing the series with the greatest potential) with the goal of identifying a series with a frontrunner compound meeting the MMV Early Lead criteria.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.3: Communicable diseases and NTDs
  2. 3.8: Achieve universal health coverage
SDG 17: Partnerships for the goals 
Partner organizations
Product Development Partnerships
Medicines for Malaria Venture
(MMV)

MMV will lead project strategy, medicinal chemistry (data analysis and compound design) and ensure alignment with global malaria elimination goals.

Intergovernmental Organizations and Multilaterals
Global Health Innovative Technology (GHIT)
Fund

GHIT will invest 539 million yen (US$4.7 million) for the development of monoclonal antibodies (mAbs) for malaria prevention.